The Hyla blood sensor will provide real-time continuous measurements of key blood parameters. Credit: Inspira Technologies / PRNewswire.

Inspira Technologies has secured approval from Sheba Medical Center’s Ethics Committee in Israel to carry out a clinical study of its Hyla blood sensor.

The medical technology company is planning to commence the Hyla blood sensor’s clinical study in the first quarter of the year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It plans to conduct the study in patients undergoing open-heart surgery at the Sheba Medical Center.

Developed using machine learning-based algorithms, the Hyla non-invasive optical blood sensor aims to provide continuous and real-time measurements of blood parameters during extracorporeal procedures.

These parameters are expected to potentially provide physicians with alerts of sudden changes in a patient’s condition or extracorporeal blood oxygenation circuit performance.

The Hyla blood sensor is being designed to act as a stand-alone device or an integrated part of the Augmented Respiration Technology (INSPIRA ART) system or Alice Device.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inspira Technologies’ INSPIRA ART system is designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, therefore reducing the need for mechanical ventilation. The system makes use of the hemo-protective flow approach.

The Alice extracorporeal blood circulation device provides cardiac and pulmonary support.

Hyla is expected to help improve patient outcomes while lowering complications and associated costs.

The clinical study aims to assess how the blood parameters measured by the new sensor correlate against the results of a standard blood gas analyser.

It is a prospective data collection study designed to integrate clinical research into the product development cycle.

Inspira’s products have not yet received approval from any regulatory entity.